



Market Data

Odyssey Health, Inc
OTC Pink: **ODYY**

Fiscal Year Ends	July 31
Most Recent Price	\$0.27
52-Week Range	\$0.11 – 0.87
Mkt Cap	\$24.92M
Shares Out	83.06M
Float	22.39M
Recent Funding	\$1.42M
Insider Ownership	28.53%

* as of May 19, 2022

<https://odysseygi.com/>

Company Overview


Odyssey Health Inc. (formerly Odyssey Group International, Inc.) is a technology and asset acquisition company with a focus in the area of life saving medical solutions.

Odyssey’s novel pharmaceutical compound, PRV-002, is intended for the treatment of concussion. PRV-002 is a new chemical entity administered nasally with proven in-vivo efficacy and safety in concussion models. Pre-clinical results show significantly improved sensory motor function and significantly improved memory scores. The drug is currently in a Phase 1 human trial.

Beyond concussion, Odyssey envisions treating related brain injuries and neurodegenerative disorders, such as Alzheimer’s, Parkinson’s, and ALS, with other novel neurosteroids.

Odyssey’s medical devices in development include the CardioMap® and Save-a-Life Device®. The CardioMap® serves as a 30-second EKG machine with a cloud-based algorithm, which provides physicians a 3D map of a patient’s heart. This provides actionable information in real time. Save-A-Life® is a patented, handheld anti-choking device that creates a vacuum chamber in the mouth to dislodge obstructions. In the U.S., choking results in 100,000 annual ER visits and is the 4th leading cause of unintentional death. Save-A-Life® is easy to use by both adults and children and can be self-administered.

Intranasal Delivery Device*



Save-a-Life*



*All products are currently in development and not commercially available

Value Proposition

Odyssey Health, Inc. has been built at the intersection of vast unmet medical needs and multiple market opportunities. The company’s drug development of its novel compound could provide the first FDA approved treatment for concussions. In the US, there are more than 5 million concussions reported each year, with more than 69 million worldwide, representing a potential \$400 billion market opportunity. Moreover, Odyssey’s medical products, which include CardioMap®, a monitoring and screening device for early detection of coronary artery disease and Save-A-Life®, a handheld choking rescue device for consumer use, address critical needs in ways that could become industry standards. These solutions are unique, and the unmet needs are so vast, Odyssey’s future is potential is promising.

RedChip Companies, Inc. research reports, company profiles and other investor relations materials, publications or presentations, including web content, are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Any opinions expressed in RedChip reports, company profiles, or other investor relations materials and presentations are subject to change. RedChip Companies and its affiliates may buy and sell shares of securities or options of the issuers mentioned on this website at any time. The information contained herein is not intended to be used as the basis for investment decisions and should not be construed as advice intended to meet the particular investment needs of any investor. The information contained herein is not a representation or warranty and is not an offer or solicitation of an offer to buy or sell any security. To the fullest extent of the law, RedChip Companies, Inc., our specialists, advisors, and partners will not be liable to any person or entity for the quality, accuracy, completeness, reliability or timeliness of the information provided, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information provided to any person or entity (including but not limited to lost profits, loss of opportunities, trading losses and damages that may result from any inaccuracy or incompleteness of this information). Stock market investing is inherently risky. RedChip Companies is not responsible for any gains or losses that result from the opinions expressed on this website, in its research reports, company profiles or in other investor relations materials or presentations that it publishes electronically or in print. We strongly encourage all investors to conduct their own research before making any investment decision. For more information on stock market investing, visit the Securities and Exchange Commission ("SEC") at www.sec.gov. Odyssey Health, Inc. is a client of RedChip Companies, Inc. ODYY agreed to pay RedChip Companies, Inc., a \$7,500 monthly cash fee, 45,000 shares of rule 144 stock, and 45,000 options, beginning in May 2022, for 5 months of RedChip investor awareness services.



Investment Highlights

- Novel compound for concussion treatment, PRV-002 – currently in Phase 1 human trials -- addresses a \$20 billion U.S. market. Science backed by industry experts.
- Strong leadership team of successful pharma and medical device industry veterans.
- Sports advisory board of NFL Hall of Famers, Super Bowl champions, an Olympic gold medalist, and head coaches and managers of other pro sports teams.
- Science advisory and military advisory board members are well regarded leaders in their fields.
- Multiple products in development with near-term milestones.
- Potential to commercialize products in 2022.
- \$500,000 donation in partnership with Erase PTSD Now and the Glenn Greenberg and Linda Vester Foundation for Phase 1 human clinical trials for drug candidate PRV-002.
- CardioMap® system has multiple end markets including hospitals, doctor offices, rehabilitation centers, and sports medicine markets.
- Save-A-Life® Device has established proof of concept with prototypes in development by industry expert Tanaka Kapek Design Group.

Directors and Officers

Michael Redmond – Director, President and CEO

Mr. Redmond has served as our Chief Executive Officer, President and Chairman of the Board since 2017. Mr. Redmond has over 30 years commercial experience in the medical device and biotech field with Abbott Laboratories, Inc., Bioject Medical Technologies, Inc., (Bioject) and KMC Systems. Mr. Redmond has raised over \$30 million in his career and entered successful collaborations with multiple big pharma and biotech companies.

Jerome H. Casey – Director

Mr. Casey has been a Director since September 2019. He has been a leader in the life science industry for over 30 years. Mr. Casey served as a President of Genzyme Diagnostics, a biotechnology company, which Genzyme sold to Japan-based Sekisui.

Jeffrey Conroy – Director

Mr. Conroy has been a Director since August 2019. Mr. Conroy is an operating and business development executive with over 30 years in the life science industry across therapeutics and medical devices. Mr. Conroy is Chairman and CEO of a medical device company focused on regenerative implants for tendon and ligament repair.

John P. Gandolfo – Director

Mr. Gandolfo has been a Director since October 2019 and Chairs the Audit Committee. Mr. Gandolfo has approximately 33 years of experience as a Chief Financial Officer (CFO) of multiple rapidly growing private and publicly held companies with a primary focus in the life sciences, healthcare and medical device areas. Mr. Gandolfo serves as CFO of Eyenovia, Inc., a late-stage ophthalmic biopharmaceutical company.

Ricky W. Richardson - Director

Mr. Richardson has been a Director since May 2021. Mr. Richardson has over 30 years of experience as a global operations and quality leader in medical devices. Mr. Richardson has held senior leadership positions at Baxter, Bioject and Danaher. He is a graduate of the United States Military Academy at West Point.

Christine M. Farrell – Chief Financial Officer and Secretary

Ms. Farrell has been with Odyssey since 2019. Ms. Farrell has over 25 years of experience in medical device and public companies and serves as our Chief Financial Officer. Prior to joining Odyssey, Ms. Farrell served as Vice President of Bioject, a publicly traded medical device company.